医療従事者の為の最新医療ニュースや様々な情報・ツールを提供する医療総合サイト

CORRECTING and REPLACING Vivimed Life Sciences Pvt Ltd Issues Voluntary Nationwide Recall of Losartan Potassium 25 mg, 50 mg and 100 mg Tablets, USP Due to the Detection of Trace Amounts of N-Nitroso-N-methyl-4-aminobutyric acid (NMBA) I

2019年05月09日 PM11:18
このエントリーをはてなブックマークに追加


 

CHENNAI, India

Please replace the release dated May 3, 2019 with the following corrected version due to multiple revisions in the first paragraph.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20190503005346/en/

25 mg 90s label for Heritage (Graphic: Business Wire)

25 mg 90s label for Heritage (Graphic: Business Wire)

The corrected release reads:

VIVIMED LIFE SCIENCES Pvt Ltd ISSUES VOLUNTARY NATIONWIDE RECALL OF LOSARTAN POTASSIUM 25 MG, 50 MG AND 100 MG TABLETS, USP DUE TO THE DETECTION OF TRACE AMOUNTS OF N-Nitroso-N-methyl-4-aminobutyric acid (NMBA) IMPURITY

Vivimed Life Sciences Pvt Ltd (Vivimed) is recalling 19 lots of Losartan Potassium Tablets USP 25 mg, 50 mg, and 100 mg to consumer level due to the detection of N-Nitroso-N-methyl-4-aminobutyric acid (NMBA), a possible process impurity or contaminant in an active pharmaceutical ingredient manufactured by Hetero Labs Limited (API manufacturer), that is above the US Food & Drug Administration’s interim acceptable exposure limit of 9.82 ppm. Based on the available information, the risk of developing cancer in a few patients following long-term use of the product containing high levels of the impurity NMBA cannot be ruled out.

This product is made by Vivimed at its Plant in Alathur, Chennai, India and Distributed by Heritage Pharmaceuticals Inc, East Brunswick NJ (Heritage). To date, neither Vivimed nor Heritage has received any reports of adverse events related to this recall.

Losartan Potassium is indicated for the treatment of hypertension, hypertensive patients with left ventricular hypertrophy, nephropathy in Type 2 diabetic patients and is packaged in 90-count and 1000-count bottles. The lots were manufactured by Vivimed at its Plant in Alathur, Chennai, India and Distributed by Heritage Pharmaceuticals Inc, East Brunswick NJ (Heritage).

The identifying NDC #s associated with Heritage distributed product are as follows:

Losartan Tablets 25 mg: 90- count: NDC 23155-644-09, Losartan Tablets 50 mg: 90- count: NDC 23155-645-09; 1000-count: NDC 23155-645-10, Losartan Tablets 100 mg: 90-count- NDC 23155-646-09 1000-count: NDC 23155-646-10.

The affected Losartan Potassium tablets, includes the 19 lot numbers which are listed below:

                         
Product Name     Lot Number     Pack     Expiry Date     Distributed by
Losartan Potassium Tablets USP, 25 mg     CLO17006A     90’s     Nov 2019     HERITAGE
Losartan Potassium Tablets USP, 50 mg     CLO17007A     1000′s     Nov 2019     HERITAGE
Losartan Potassium Tablets USP, 50 mg     CLO17008A     1000′s     Nov 2019     HERITAGE
Losartan Potassium Tablets USP, 50 mg     CLO17009A     1000′s     Nov 2019     HERITAGE
Losartan Potassium Tablets USP, 50 mg     CLO17009B     90′s     Nov 2019     HERITAGE
Losartan Potassium Tablets USP, 50 mg     CLO17010A     90′s     Nov 2019     HERITAGE
Losartan Potassium Tablets USP, 100 mg     CLO17012A     90′s     Nov 2019     HERITAGE
Losartan Potassium Tablets USP, 100 mg     CLO17013A     90′s     Nov 2019     HERITAGE
Losartan Potassium Tablets USP, 100 mg     CLO17014A     1000′s     Dec 2019     HERITAGE
Losartan Potassium Tablets USP, 100 mg     CLO17015A     1000′s     Jan 2020     HERITAGE
Losartan Potassium Tablets USP, 100 mg     CLO17016A     1000′s     Jan 2020     HERITAGE
Losartan Potassium Tablets USP, 100 mg     CLO17017A     1000′s     Jan 2020     HERITAGE
Losartan Potassium Tablets USP, 100 mg     CLO18001A     1000′s     Jan 2020     HERITAGE
Losartan Potassium Tablets USP, 100 mg     CLO18002A     90′s     Jan 2020     HERITAGE
Losartan Potassium Tablets USP, 100 mg     CLO18002B     1000′s     Jan 2020     HERITAGE
Losartan Potassium Tablets USP, 100 mg     CLO18020A     90′s     Apr 2020     HERITAGE
Losartan Potassium Tablets USP, 100 mg     CLO18021A     90′s     Apr 2020     HERITAGE
Losartan Potassium Tablets USP, 100 mg     CLO18022A     90′s     Apr 2020     HERITAGE
Losartan Potassium Tablets USP, 50 mg     CLO18023A     90′s     Apr 2020     HERITAGE
               

Losartan Potassium Tablets were distributed Nationwide to Wholesalers, Distributors, Retail Pharmacies, and Mail Order Pharmacies.

Inmar is notifying distributors and other customers by recall notification and arranging for return of recalled product of Losartan Potassium Tablets from the above lots.

Consumers should contact their doctor for further guidance and potential change of treatment before they stop taking the product. Pharmacies and healthcare facilities that have the product being recalled from above listed lots should stop using and dispensing the product immediately. Consumers should contact their physician or healthcare provider if they have experienced any problems that may be related to taking or using this drug product.

Consumers with questions regarding this recall can contact Vivimed c/o Inmar at 1-877-861-3811 Monday – Friday, 9am – 5pm EST.

Adverse reactions or quality problems associated with the use of this product may be reported to FDA’s MedWatch Adverse Event Reporting program either by phone, online, by regular mail or by fax.

This recall is being conducted with the knowledge of the U.S. Food and Drug Administration.

View source version on businesswire.com: https://www.businesswire.com/news/home/20190503005346/en/

CONTACT

Consumers

Vivimed Life Sciences Pvt Ltd
C/O Inmar Inc
Email: rxrecalls@inmar.com
1-877-861-3811

Media

Inmar Inc
Contact Name: Mr. Jack Patterson
Phone#
1-877-861-3811
Email: rxrecalls@inmar.com

Related Posts Plugin for WordPress, Blogger...

同じカテゴリーの記事 

  • Masimo O3®を使用してCOVID-19患者の脳酸素化に及ぼす換気補助療法の影響を追究した研究
  • CoVIg-19プラズマ・アライアンス、COVID-19治療薬候補の高度免疫グロブリン製剤を評価するためにNIHが実施した臨床試験のトップライン結果を発表
  • CoVIg-19血浆联盟公布NIH发起的在研药物COVID-19超免疫球蛋白临床试验的顶线结果
  • DESTINY-CRC02 Phase 2 Trial of ENHERTU® Initiated in Patients with HER2 Overexpressing Advanced Colorectal Cancer
  • HempFusion’s Products Enter Asia Through Alibaba Group’s Tmall Global